Marksans Pharma has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg. It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose. The product will be marketed under store brand labels and is comparable to the brand Zyrtec.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
